Trading Analysis Report: MD
- Analysis date: 2026-05-31
- Processed decision: Hold
- Price Target: 24
I. Analyst Team Reports
Market Analyst
Market Report
Pediatrix Medical Group (MD) closed at $21.54 on May 29, 2026, slightly below its $22.04 50-day average but above its $20.30 200-day average.
The stock has already moved sharply. Local yfinance history showed a one-year price return of about 52.2%, while the 52-week range was $11.84-$24.99.
Valuation is still reasonable. yfinance showed trailing P/E of 10.46x, forward P/E of 9.13x, price/sales of 0.92x, price/book of 1.96x, and ROE of 20.89%.
Analyst targets suggest limited remaining upside, with yfinance mean target of $23.17 and median target of $23.50.
Market read: MD is fundamentally improved, but upside is moderate after a strong rally. Assign Hold with a $24 target.
Sentiment Analyst
Sentiment Report
Sentiment is constructive but not aggressive.
Q1 2026 adjusted EPS was $0.44, up from $0.33, and adjusted EBITDA was $58.2 million, up from $49.2 million.
Management reaffirmed 2026 adjusted EBITDA outlook of $280-$300 million, supporting confidence in the turnaround.
The caution is that the stock already rose more than 52% over the last year and trades close to the median analyst target.
Sentiment read: positive enough to hold, but not enough for a fresh Buy at the current price.
News Analyst
News Report
The key current source is Pediatrix's Q1 2026 results release.
Q1 2026 net revenue was $476.2 million, up from $458.4 million. Net income was $29.6 million, up from $20.7 million.
Reported earnings were $0.36 per share, and adjusted EPS was $0.44.
Same-unit revenue grew 2.8%. Net reimbursement-related factors contributed 4.4%, while patient volume reduced same-unit revenue by 1.6%.
Hospital-based patient services volume decreased 1.5%, office-based patient services volume decreased 3.3%, and NICU days decreased 0.8%.
News read: pricing/reimbursement is offsetting volume pressure, which supports Hold but leaves risk.
Fundamentals Analyst
Fundamentals Report
MD has improving fundamentals and a manageable valuation.
yfinance showed TTM revenue of about $1.932 billion, EBITDA of $261.572 million, operating margin of 9.781%, profit margin of 9.019%, ROA of 7.350%, and ROE of 20.893%.
Cash and debt require context. The company reported cash and cash equivalents of $205.8 million at March 31, 2026 and total debt of $591 million. There were no outstanding borrowings under its $450 million revolving line of credit.
Q1 cash flow was seasonally negative, with $129.5 million used by continuing operations, reflecting typical first-quarter compensation and benefit matching payments.
Fundamental read: the business is stable, but volume pressure and healthcare payor risk prevent a stronger rating.
II. Research Team Decision
Bull Researcher
Bull Research
The bull case is improved earnings, low valuation, and reaffirmed guidance.
Adjusted EBITDA increased to $58.2 million, adjusted EPS increased to $0.44, and management reaffirmed $280-$300 million of 2026 adjusted EBITDA.
yfinance showed forward P/E of only 9.13x and ROE of 20.89%.
The company also has meaningful liquidity, including a $450 million undrawn revolver.
Bull conclusion: MD can move higher if volume stabilizes and reimbursement stays favorable.
Bear Researcher
Bear Research
The bear case is that the rally has already captured much of the improvement.
The stock gained about 52.2% over one year and trades close to the yfinance median target of $23.50.
Operationally, same-unit revenue growth depended on reimbursement. Patient volume reduced same-unit revenue by 1.6%, hospital-based volume declined 1.5%, office-based volume declined 3.3%, and NICU days declined 0.8%.
The company also faces risks from healthcare reform, payors, Medicaid, surprise billing, revenue-cycle transition, acquisitions, and debt financing.
Bear conclusion: Hold is more appropriate than Buy until volume improves.
Research Manager
Research Manager Synthesis
The bull case is strong enough to avoid a Sell: adjusted EBITDA improved, guidance was reaffirmed, valuation is reasonable, and cash flow should normalize after Q1 seasonality.
The bear case is also real: volume is declining, the stock has already rallied, and the target-price spread is not large.
The correct conclusion is Hold. A $24 target gives modest upside and sits below the $24.99 52-week high.
Synthesis: assign Hold with a $24 target.
III. Trading Team Plan
Trader
Trader View
MD is above the 200-day average but just below the 50-day average.
Upside trigger: a move back above the 50-day average near $22.04, continued adjusted EBITDA strength, and stabilized patient volumes.
Downside trigger: loss of the 200-day average near $20.30, weaker volume, or reimbursement/payor pressure.
Trading plan: hold current exposure and add only on pullbacks or evidence of volume stabilization.
IV. Risk Management Team Decision
Aggressive Analyst
Aggressive Risk View
Aggressive investors may hold MD because the valuation is low and the company reaffirmed its EBITDA outlook.
The high target in yfinance was $27.00, showing some upside if execution remains strong.
The risk is that volume weakness offsets reimbursement gains and the stock derates after a strong rally.
Aggressive conclusion: Hold, with selective adds only after confirmation.
Conservative Analyst
Conservative Risk View
Conservative investors can hold MD, but should avoid chasing after the one-year rally.
The business has healthcare payor and regulatory risks, and Q1 same-unit revenue growth depended on net reimbursement rather than volume.
Liquidity is reasonable because the revolver was undrawn, but debt of $591 million still needs monitoring.
Conservative conclusion: Hold.
Neutral Analyst
Neutral Risk View
The neutral view is that MD is a better company than it was a year ago, but the stock already reflects much of that improvement.
The positives are adjusted EBITDA growth, reaffirmed guidance, low P/E, and ROE. The negatives are volume pressure, healthcare payor risk, and limited target spread.
The $24 target reflects moderate upside.
Neutral conclusion: Hold.
V. Portfolio Manager Decision
Portfolio Manager
Portfolio Manager Decision
Rating: Hold Price Target: 24
Horizon: 6-12 months Current Price Reference: $21.54 close on 2026-05-29
Pediatrix Medical Group is rated Hold. Q1 2026 results improved, but the share price already reflects much of the recovery. Net revenue rose to $476.2 million from $458.4 million, net income rose to $29.6 million, adjusted EPS improved to $0.44, and adjusted EBITDA rose to $58.2 million.
Management reaffirmed 2026 adjusted EBITDA guidance of $280-$300 million, and yfinance showed reasonable valuation at 9.13x forward earnings with ROE of 20.893%.
The main risk is mix quality. Same-unit revenue rose 2.8%, but that came from 4.4% reimbursement-related growth while patient volume reduced revenue by 1.6%. Hospital-based and office-based volumes declined, and NICU days were lower.
The $24 target is slightly above the yfinance median analyst target of $23.50 and below the $24.99 52-week high. Hold reflects moderate upside, valuation support, and continuing volume/payor risk.